Skip to main content
Top

Open Access 11-01-2025 | Progressive Supranuclear Palsy | Review Article

A smart tool for non expert clinicians for the dissemination of the MDS criteria for progressive supranuclear palsy

Authors: Marina Picillo, Filomena Abate, Vincenzo Canoro, Maria Francesca Tepedino, Paolo Barone, Roberto Erro

Published in: Neurological Sciences

Login to get access

Abstract

Due to the variety of clinical phenotypes and the massive clinical overlap with other neurodegenerative diseases, the diagnosis of Progressive Supranuclear Palsy (PSP) remains a major challenge. Notwithstanding, early and reliable clinical diagnosis of PSP is highly warranted for estimation of prognosis, appropriate allocation to therapeutic trials and development of new diagnostic tools. As reliable biomarkers are lacking, PSP diagnosis relies on the application of the clinical criteria promoted by the International Parkinson and Movement Disorder Society (MDS). Despite providing a framework including all the main PSP cornerstones (ocular dysfunction and postural instability, akinesia and cognitive dysfunction), the application of the MDS PSP criteria is complex and not straightforward to apply in a clinical setting. Herein we propose a practical tool, including a video-guided slide-set and a smartsheet, to disseminate the MDS PSP clinical criteria among healthy practitioners and increase confidence in non expert clinicians towards suspicion and diagnosis of PSP. The video-guided slide set may serve as a teaching resource for both general neurologists and practitioners, while the smartsheet may represent a valid support in attributing the degree of diagnostic certainty and phenotype based on the identified clinical features. Application of our tool may improve early recognition of patients in primary and secondary care and determine a prompt referral to third level movement disorder centers for consideration in clinical trials testing disease-modifying treatments.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hoglinger GU, Respondek G, Stamelou M, for the Movement Disorder Society–endorsed PSP Study Group et al (2017) Clinical diagnosis of Progressive Supranuclear Palsy: the Movement Disorder Society Criteria. Mov Disord 32:853–864CrossRefPubMedPubMedCentral Hoglinger GU, Respondek G, Stamelou M, for the Movement Disorder Society–endorsed PSP Study Group et al (2017) Clinical diagnosis of Progressive Supranuclear Palsy: the Movement Disorder Society Criteria. Mov Disord 32:853–864CrossRefPubMedPubMedCentral
2.
go back to reference Litvan I, Hauw JJ, Bartko JJ et al (1996) Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 55:97–105CrossRefPubMed Litvan I, Hauw JJ, Bartko JJ et al (1996) Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 55:97–105CrossRefPubMed
3.
go back to reference Litvan I, Agid Y, Calne D et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47:1–9 Litvan I, Agid Y, Calne D et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47:1–9
4.
go back to reference Grimm MJ, Respondek G, Stamelou M et al (2019) How to apply the Movement Disorder Society Criteria for Diagnosis of Progressive Supranuclear Palsy. Mov Disord 34:1228–1232CrossRefPubMedPubMedCentral Grimm MJ, Respondek G, Stamelou M et al (2019) How to apply the Movement Disorder Society Criteria for Diagnosis of Progressive Supranuclear Palsy. Mov Disord 34:1228–1232CrossRefPubMedPubMedCentral
5.
go back to reference Picillo M, Erro R, Cuoco S, Tepedino MF, Manara R, Pellecchia MT, Barone P, PSP Salerno Study Group (2018) MDS PSP criteria in real-life clinical setting: motor and cognitive characterization of subtypes. Mov Disord 33(8):1361–1365CrossRefPubMed Picillo M, Erro R, Cuoco S, Tepedino MF, Manara R, Pellecchia MT, Barone P, PSP Salerno Study Group (2018) MDS PSP criteria in real-life clinical setting: motor and cognitive characterization of subtypes. Mov Disord 33(8):1361–1365CrossRefPubMed
6.
go back to reference Picillo M, Cuoco S, Tepedino MF, Cappiello A, Volpe G, Erro R, Santangelo G, Pellecchia MT, Barone P, PSP Salerno study group (2019) Motor, cognitive and behavioral differences in MDS PSP phenotypes. J Neurol 266(7):1727–1735CrossRefPubMed Picillo M, Cuoco S, Tepedino MF, Cappiello A, Volpe G, Erro R, Santangelo G, Pellecchia MT, Barone P, PSP Salerno study group (2019) Motor, cognitive and behavioral differences in MDS PSP phenotypes. J Neurol 266(7):1727–1735CrossRefPubMed
7.
go back to reference Goetz CG, Fahn S, Martinez-Martin P et al (2007) Movement Disorder Society‐Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS‐UPDRS): process, format, and clinimetric testing plan. Mov Disord 22(1):41–47CrossRefPubMed Goetz CG, Fahn S, Martinez-Martin P et al (2007) Movement Disorder Society‐Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS‐UPDRS): process, format, and clinimetric testing plan. Mov Disord 22(1):41–47CrossRefPubMed
8.
go back to reference Boxer A, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 16:552–563CrossRefPubMedPubMedCentral Boxer A, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 16:552–563CrossRefPubMedPubMedCentral
9.
go back to reference Respondek G, Grimm MJ, Piot I et al (2020) Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. Mov Disord 35(1):171–176CrossRefPubMed Respondek G, Grimm MJ, Piot I et al (2020) Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. Mov Disord 35(1):171–176CrossRefPubMed
10.
go back to reference Street Duncan, Whiteside D, Rittman T, Rowe JB (2022) Prodromal Progressive Supranuclear Palsy-insights from the UK Biobank. Parkinsonism Relat Disord 95:59–64CrossRefPubMed Street Duncan, Whiteside D, Rittman T, Rowe JB (2022) Prodromal Progressive Supranuclear Palsy-insights from the UK Biobank. Parkinsonism Relat Disord 95:59–64CrossRefPubMed
11.
go back to reference Kwasny MJ, Oleske DM, Zamudio J, Diegidio R, Hoglinger GU (2021) Clinical features observed in general practice associated with the susequent diagnosis of progressive supranuclear palsy. Front Neurol 12:637176CrossRefPubMedPubMedCentral Kwasny MJ, Oleske DM, Zamudio J, Diegidio R, Hoglinger GU (2021) Clinical features observed in general practice associated with the susequent diagnosis of progressive supranuclear palsy. Front Neurol 12:637176CrossRefPubMedPubMedCentral
12.
go back to reference Painous C, Martí MJ, Simonet C, Garrido A, Valldeoriola F, Muñoz E, Cámara A, Compta Y (2020) Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: the step-back PSP study. Parkinsonism Relat Disord 74:67–73CrossRefPubMed Painous C, Martí MJ, Simonet C, Garrido A, Valldeoriola F, Muñoz E, Cámara A, Compta Y (2020) Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: the step-back PSP study. Parkinsonism Relat Disord 74:67–73CrossRefPubMed
13.
go back to reference Grimm MJ, Respondek G, Stamelou M, Arzberger T et al (2020) Clinical conditions suggestive of progressive supranuclear palsy-diagnostic performance. Mov Disord 35(12):2301–2313CrossRefPubMedPubMedCentral Grimm MJ, Respondek G, Stamelou M, Arzberger T et al (2020) Clinical conditions suggestive of progressive supranuclear palsy-diagnostic performance. Mov Disord 35(12):2301–2313CrossRefPubMedPubMedCentral
14.
go back to reference Tsai RM, Miller Z, Koestler M et al (2020) Reactions to multiple ascending doses of the Microtubule stabilizer TPI-287 in patients with Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: a Randomized Clinical Trial. JAMA Neurol 77(2):215–224CrossRefPubMed Tsai RM, Miller Z, Koestler M et al (2020) Reactions to multiple ascending doses of the Microtubule stabilizer TPI-287 in patients with Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: a Randomized Clinical Trial. JAMA Neurol 77(2):215–224CrossRefPubMed
15.
go back to reference Iankova V, Respondek G, Saranza G et al (2020) Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. Parkinsonism Relat Disorders 78:200–203CrossRef Iankova V, Respondek G, Saranza G et al (2020) Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. Parkinsonism Relat Disorders 78:200–203CrossRef
16.
17.
go back to reference Abate F, Picillo M, Della Rocca G, Barone P, Erro R (2020) The zig-zag sign in Progressive Supranuclear Palsy. Parkinsonism Relat Disord 79:86–87CrossRefPubMed Abate F, Picillo M, Della Rocca G, Barone P, Erro R (2020) The zig-zag sign in Progressive Supranuclear Palsy. Parkinsonism Relat Disord 79:86–87CrossRefPubMed
18.
go back to reference Fearon C, Field R, Donlon E et al (2020) The round the houses sign and zig-zag sign in progressive supranuclear palsy and other conditions. Parkinsonism Relat Disord 81:94–95CrossRefPubMed Fearon C, Field R, Donlon E et al (2020) The round the houses sign and zig-zag sign in progressive supranuclear palsy and other conditions. Parkinsonism Relat Disord 81:94–95CrossRefPubMed
19.
go back to reference Romano S, Colosimo C (2001) Procerus sign in progressive supranuclear palsy. 57(10):1928 Romano S, Colosimo C (2001) Procerus sign in progressive supranuclear palsy. 57(10):1928
20.
go back to reference Marsili L, Colosimo C (2020) The gunslinger sign in progressive supranuclear palsy - Richardson variant. J Neurol Sci 418:117108CrossRefPubMed Marsili L, Colosimo C (2020) The gunslinger sign in progressive supranuclear palsy - Richardson variant. J Neurol Sci 418:117108CrossRefPubMed
21.
go back to reference Adachi M, Kawanami T, Ohshima H et al (2004) Morning glory sign: a particular MR finding in progressive supranuclear palsy. Magn Reson Med Sci 3:125–132CrossRefPubMed Adachi M, Kawanami T, Ohshima H et al (2004) Morning glory sign: a particular MR finding in progressive supranuclear palsy. Magn Reson Med Sci 3:125–132CrossRefPubMed
22.
go back to reference Gröschel K, Kastrup A, Litvan I et al (2006) Penguins and hummingbirds: midbrain atrophy in progressive supranuclear palsy. Neurology 66:949–950CrossRefPubMed Gröschel K, Kastrup A, Litvan I et al (2006) Penguins and hummingbirds: midbrain atrophy in progressive supranuclear palsy. Neurology 66:949–950CrossRefPubMed
23.
go back to reference Picillo M, Tepedino MF, Abate F et al (2020) Midbrain MRI assessments in progressive supranuclear palsy subtypes. 2020, Journal of Neurology, Neurosurgery and Psychiatry 91:98–103 Picillo M, Tepedino MF, Abate F et al (2020) Midbrain MRI assessments in progressive supranuclear palsy subtypes. 2020, Journal of Neurology, Neurosurgery and Psychiatry 91:98–103
24.
go back to reference Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE (2001) Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 7:7–27 Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE (2001) Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 7:7–27
Metadata
Title
A smart tool for non expert clinicians for the dissemination of the MDS criteria for progressive supranuclear palsy
Authors
Marina Picillo
Filomena Abate
Vincenzo Canoro
Maria Francesca Tepedino
Paolo Barone
Roberto Erro
Publication date
11-01-2025
Publisher
Springer International Publishing
Published in
Neurological Sciences
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-025-07996-0

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Advances in Alzheimer's

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Learn more